Form 4: MaxCyte Director John Johnston Receives Annual Equity Grant

MaxCyte, Inc. Director John Joseph Johnston was granted 29,210 restricted stock units and 50,790 stock options as part of his annual compensation, increasing his beneficial ownership.

Summary

• John Joseph Johnston, a Director of MaxCyte, Inc. (MXCT), received an annual equity grant on June 18, 2025.
• The grant included 29,210 Restricted Stock Units (RSUs), each convertible into one share of Common Stock, granted at a price of $0.
• These RSUs will vest on June 18, 2026, contingent on Mr. Johnston's continuous service.
• Additionally, Mr. Johnston was granted 50,790 stock options with an exercise price of $2.11 per share, also granted at a price of $0.
• The stock options are exercisable as of June 18, 2025, and expire on June 17, 2035.
• Following these transactions, Mr. Johnston beneficially owns 171,160 shares of Common Stock and 50,790 stock options.
• The grants were made under MaxCyte's Equity Grant Policy for non-employee directors.

Sentiment

Score: 7

Explanation: The filing indicates a routine annual equity grant to a director, which is a positive for aligning management interests with shareholders. There are no negative disclosures. The grant itself is a positive for the director and implies continued commitment.

Positives

• Director John Johnston received a significant annual equity grant, aligning his interests with shareholders.
• The grant includes both restricted stock units and stock options, providing a mix of immediate and long-term incentives.
• The stock options have a 10-year expiration, offering a long window for potential value realization.

Corporate Governance

Related Party Transactions

• Annual equity grants of 29,210 Restricted Stock Units and 50,790 stock options to Director John Joseph Johnston, made pursuant to the Issuer's Equity Grant Policy for non-employee directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by providing equity-based compensation, potentially incentivizing long-term value creation. Minor dilution from new shares issued for RSUs and options is a consideration.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The Restricted Stock Units are scheduled to vest on June 18, 2026, subject to continuous service.
• The stock options are exercisable from June 18, 2025, until their expiration on June 17, 2035.

Key Dates

Recommendation

Keywords

MaxCyte, MXCT, Form 4, SEC filing, insider transaction, equity grant, restricted stock units, RSUs, stock options, director compensation, beneficial ownership